EA030005B1 - Композиции и способы лечения грибковых и бактериальных патогенов - Google Patents

Композиции и способы лечения грибковых и бактериальных патогенов Download PDF

Info

Publication number
EA030005B1
EA030005B1 EA201591808A EA201591808A EA030005B1 EA 030005 B1 EA030005 B1 EA 030005B1 EA 201591808 A EA201591808 A EA 201591808A EA 201591808 A EA201591808 A EA 201591808A EA 030005 B1 EA030005 B1 EA 030005B1
Authority
EA
Eurasian Patent Office
Prior art keywords
thb
polypeptide
sequence
amino acid
azp
Prior art date
Application number
EA201591808A
Other languages
English (en)
Russian (ru)
Other versions
EA201591808A1 (ru
Inventor
Ашраф С. Ибрагим
Майкл Р. Йиман
Скотт Дж. Филлер
Джон Е. Джр. Эдвардс
Джон П. Джр. Хеннеси
Original Assignee
Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер
Новадигм Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер, Новадигм Терапьютикс, Инк. filed Critical Лос-Анджелес Биомедикал Ресерч Институт Эт Харбор-Укла Медикал Центер
Publication of EA201591808A1 publication Critical patent/EA201591808A1/ru
Publication of EA030005B1 publication Critical patent/EA030005B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/165—Yeast isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi
    • C12R2001/72—Candida
    • C12R2001/725—Candida albicans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EA201591808A 2013-03-15 2014-03-14 Композиции и способы лечения грибковых и бактериальных патогенов EA030005B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789091P 2013-03-15 2013-03-15
PCT/US2014/028521 WO2014144211A2 (en) 2013-03-15 2014-03-14 Compositions and methods for treating fungal and bacterial pathogens

Publications (2)

Publication Number Publication Date
EA201591808A1 EA201591808A1 (ru) 2016-02-29
EA030005B1 true EA030005B1 (ru) 2018-06-29

Family

ID=51538308

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591808A EA030005B1 (ru) 2013-03-15 2014-03-14 Композиции и способы лечения грибковых и бактериальных патогенов

Country Status (12)

Country Link
US (2) US10130691B2 (enExample)
EP (1) EP2968497B1 (enExample)
JP (2) JP6591961B2 (enExample)
CN (1) CN105407915A (enExample)
AU (1) AU2014227748B2 (enExample)
BR (1) BR112015022963A8 (enExample)
CA (1) CA2906771A1 (enExample)
EA (1) EA030005B1 (enExample)
MD (1) MD20150098A2 (enExample)
MX (1) MX2015012681A (enExample)
RU (1) RU2717306C2 (enExample)
WO (1) WO2014144211A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
BR112015022963A8 (pt) 2013-03-15 2018-01-16 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct composições e métodos para tratar patógenos fúngicos e bacterianos.
WO2017155949A1 (en) * 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
JP7439371B2 (ja) 2018-04-10 2024-02-28 ロサンゼルス バイオメディカル リサーチ インスティテュート アット ハーバー－ ユーシーエルエー メディカル センター Ｃａｎｄｉｄａ ａｕｒｉｓ感染症の治療方法
JP2022522023A (ja) 2019-02-28 2022-04-13 ユニベルズィダード ドゥ ミンホ カンジダ・アルビカンス感染をコントロールするためのアンチセンスオリゴマー
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases
WO2025248488A1 (en) * 2024-05-29 2025-12-04 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Compositions and methods for preventing and treating healthcare-associated candida auris infections with dual antigen vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036817A2 (en) * 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
WO2013015831A1 (en) * 2011-07-22 2013-01-31 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against staphylococcus aureus

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995031998A1 (en) 1994-05-23 1995-11-30 The Research & Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
US6500438B2 (en) 1995-06-07 2002-12-31 Pfizer Incorporated In ovo vaccination against coccidiosis
US6288214B1 (en) 1996-05-16 2001-09-11 Texas A&M University Systems Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
ES2645563T3 (es) 2001-11-30 2017-12-05 Amgen Fremont Inc. Animales transgénicos que portan genes de cadena ligera de Ig humana
CA2486618C (en) 2002-05-21 2013-04-09 Schering-Plough Ltd. Methods for the in vitro culture of sporozoea sp. and uses thereof
US7241613B1 (en) 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
BRPI0416205A (pt) 2003-11-21 2006-12-26 Pfizer Prod Inc uso de antibióticos como adjuvantes de vacina
US20050287146A1 (en) 2003-12-19 2005-12-29 Joseph Patti Method of inhibiting Candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
WO2007123850A2 (en) 2006-04-17 2007-11-01 Schering-Plough Ltd. Recombinant attenuated clostridium organisms and vaccine
WO2008147847A1 (en) 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2296698A1 (en) 2008-05-29 2011-03-23 Intervet International BV Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
AU2010264538B2 (en) 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
ES2606555T3 (es) * 2009-07-03 2017-03-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center HYR1 como objetivo para la inmunización activa y pasiva contra Candida
ES2679995T3 (es) * 2011-03-11 2018-09-03 Vib Vzw Moléculas y métodos para la inhibición y detección de proteínas
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
AU2012308281A1 (en) 2011-09-14 2014-04-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1-derived compositions and methods of treatment using same
US20160030533A1 (en) 2013-03-15 2016-02-04 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods of treating fungal and bacterial pathogens
WO2014144024A1 (en) 2013-03-15 2014-09-18 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 compositions and methods for treating fungal and bacterial pathogens
BR112015022963A8 (pt) 2013-03-15 2018-01-16 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct composições e métodos para tratar patógenos fúngicos e bacterianos.
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036817A2 (en) * 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
WO2013015831A1 (en) * 2011-07-22 2013-01-31 Novadigm Therapeutics, Inc. Methods and compositions for vaccinating against staphylococcus aureus

Also Published As

Publication number Publication date
US10130691B2 (en) 2018-11-20
EP2968497B1 (en) 2020-08-12
MX2015012681A (es) 2018-05-17
EP2968497A2 (en) 2016-01-20
JP2016515516A (ja) 2016-05-30
AU2014227748A1 (en) 2015-10-08
CA2906771A1 (en) 2014-09-18
EP2968497A4 (en) 2016-11-30
RU2015144090A (ru) 2017-04-19
BR112015022963A8 (pt) 2018-01-16
WO2014144211A8 (en) 2015-10-08
US20190030141A1 (en) 2019-01-31
MD20150098A2 (ro) 2016-02-29
CN105407915A (zh) 2016-03-16
WO2014144211A2 (en) 2014-09-18
US20160030534A1 (en) 2016-02-04
WO2014144211A3 (en) 2015-11-19
AU2014227748B2 (en) 2019-02-14
EA201591808A1 (ru) 2016-02-29
JP2019110918A (ja) 2019-07-11
JP6591961B2 (ja) 2019-10-16
RU2717306C2 (ru) 2020-03-19
BR112015022963A2 (pt) 2017-11-14

Similar Documents

Publication Publication Date Title
ES2348792T3 (es) TERAPIAS COMBINADAS DIRIGIDAS A MÚLTIPLES RECEPTORES TIPO TOLL Y USO DE LAS MISMAS.
RU2717306C2 (ru) Композиции и способы лечения грибковых и бактериальных патогенов
ES3041237T3 (en) Mutant fragments of ospa and methods and uses relating thereto
De Amicis et al. Analysis of the coverage capacity of the StreptInCor candidate vaccine against Streptococcus pyogenes
US10160790B2 (en) HYR1-derived compositions and methods of treatment using same
US20190048055A1 (en) Alt-803 in combination with anti-cd38 antibody for cancer therapies
ES2420654T3 (es) Una vacuna que comprende un antígeno conjugado con anticuerpos anti-CD40 de valencia baja
JP2021510169A (ja) アトピー性皮膚炎の治療及び／または予防のためのｉｌ−３１のペプチド免疫原ならびにその製剤
CN102924576A (zh) 幽门螺杆菌免疫显性表位肽及其制备方法和应用
WO2014144024A1 (en) Hyr1 compositions and methods for treating fungal and bacterial pathogens
WO2014144222A2 (en) Compositions and methods of treating fungal and bacterial pathogens
WO2024036166A1 (en) Bioorthogonal t cell receptor molecules and methods of making and using the same
US20030229454A1 (en) Use of a computer to design a molecule
JPWO2006041157A1 (ja) 動物の免疫方法、免疫用組成物、抗体の製造方法、ハイブリドーマの製造方法、及びモノクローナル抗体の製造方法
CN103539840B (zh) 表皮生长因子受体模拟表位肽及其应用
WO2011097216A1 (en) Vaccine and methods of use against strongyloides stercoralis infection
CN102127147B (zh) 表皮生长因子受体模拟表位肽及其应用
JP4284490B2 (ja) ｅｒｂＢ−２関連ペプチド
ES2441880A1 (es) Composición basada en polipéptidos para el tratamiento de miasis
HK1230629A1 (en) Novel vaccines against hpv and hpv-related diseases
HK1227901A1 (en) Mutant fragments of ospa and methods and uses relating thereto

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU